USPTO serial 79304640
TIGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 22, 2022
- Examiner
- BLAZICH, JOAN MICHELE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with TIGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Stacey Halpern
Stacey Halpern Knobbe, Martens, Olson & Bear, LLP2040 Main Street, 14th FloorIrvine, CA 92614UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biochemical, biological and biotechnological preparations, namely, polypeptides and proteins, for use in industry and science; chemical, biochemical, biological and biotechnological preparations, namely, polypeptides and proteins, for use in the development being the manufacture, and manufacture of reagents for industrial or scientific use; chemical, biochemical, biological and biotechnological preparations, namely, polypeptides or proteins, for use of laboratories, diagnostics and analyses for industrial or scientific use; chemical, biochemical, biological and biotechnological substances, namely, polypeptides and proteins, for use in the manufacture of pharmaceuticals | ACTIVE | — |
| 005 | Pharmaceutical products and medical preparations, namely, gene-modified and non-gene-modified cellular therapies for the treatment of localized and systemic malignant hematological and oncological diseases, genetic diseases, autoimmune diseases and infectious diseases | ACTIVE | — |
| 010 | Medical instruments, equipment and apparatus, namely, instruments, equipment and apparatus for cell and cell material collection, thawing, washing, selection, expansion, modification, harvesting, final formulation, freezing, storage and infusion into a patient in the fields of genetic diseases, autoimmune diseases, infectious diseases, localized and systemic malignant hematological and oncological diseases and other cell and cell-material based diseases and conditions | ACTIVE | — |
| 042 | Scientific research, technological development of new products for third parties; medical research; scientific and industrial research in biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious and tumor diseases; research in the field of biomedical and phytopharmaceutical technology; scientific laboratory services; pharmaceutical research and development services; scientific services, namely, development of medicines, active substances and vaccines; scientific services, namely, development of food supplement; design and development of computer hardware and software for use in medical and scientific research and in the development of new products, in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; upgrading, maintenance and rental of computer software; updating, maintenance and rental of computer software for use in medical and scientific research and in the development of new products, in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; software as a service (SaaS) services featuring software for controlling end-to-end process development, manufacturing, quality, and supply chain steps and featuring artificial intelligence search engine software to be used in medical and scientific research and in the development of new products in research and development of new products in the field of biotechnology, biology, diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases and the treatment of diseases, genetic diseases, autoimmune diseases, infectious diseases and tumor diseases; chemical and biological laboratory services | ACTIVE | — |
| 044 | Medical services; pharmacy advice services, namely, pharmaceutical consultation; medical clinic services provided by medical laboratories for diagnostic purposes; preparation and dispensing of medication; preparation of prescriptions by pharmacists | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Tigen Pharma SA
- Other trademarks owned by Tigen Pharma SA
- Other trademarks owned by Tigen Pharma SA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named TIGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 13, 2025 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jun 6, 2025 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Dec 31, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 5, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 15, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 15, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 22, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 22, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 4, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 4, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 1, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 15, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 15, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 15, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 29, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 29, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 29, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 29, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 29, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 8, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 8, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 8, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 27, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 20, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 31, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 7, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 7, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 4, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 3, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 24, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 23, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 19, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 18, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |